Tenecteplase for Acute Non–Large Vessel Occlusion After Ischemic Stroke—Reply

The article presents a reply from the authors to comments by Dr. Morelli and colleagues regarding the OPTION trial. The study addresses the use of tenecteplase in treating patients with acute ischemic stroke caused by occlusion of smaller blood vessels in the brain. Tenecteplase is a fibrinolytic medication designed to dissolve blood clots in cerebral arteries. The authors' response addresses specific questions and remarks concerning the methodology and results of this clinical trial. The article represents a scientific discussion among researchers about the efficacy and safety of this treatment approach.